One-Year Treatment With Exenatide Improves β-Cell Function, Compared With Insulin Glargine, in Metformin-Treated Type 2 Diabetic Patients

Abstract

OBJECTIVE — Traditional blood glucose–lowering agents do not sustain adequate glycemic control in most type 2 diabetic patients. Preclinical studies with exenatide have suggested sustained improvements in -cell function. We investigated the effects of 52 weeks of treatment with exenatide or insulin glargine followed by an off-drug period on hyperglycemic… (More)

Topics

4 Figures and Tables

Cite this paper

@article{Bunck2009OneYearTW, title={One-Year Treatment With Exenatide Improves β-Cell Function, Compared With Insulin Glargine, in Metformin-Treated Type 2 Diabetic Patients}, author={Mathijs C Bunck and Michaela Diamant and Anja Corn{\'e}r and Bjorn Eliasson and Jaret L. Malloy and Rimma M. Shaginian and Wei Deng and David M. Kendall and Marja-Riitta Taskinen and Ulf Smith and Hannele Yki-J{\"a}rvinen and Robert J. Heine}, journal={Diabetes Care}, year={2009}, volume={32}, pages={762 - 768} }